Meglitinides: meal-timed dosing, hypoglycaemia and how they differ from sulfonylureas

A short insulin burst tied to each meal

Meglitinides close ATP-sensitive potassium channels on pancreatic beta cells, the same target as sulfonylureas, but they bind at a different site and act quickly for a short time. The result is a pulse of insulin that blunts the glucose rise after eating. They need working beta cells, so they are not used in type 1 diabetes.

Because of this timing, the dose is taken shortly before each main meal, typically within about half an hour. A patient who adds a meal may take an extra dose under the prescribed plan, while one who skips a meal skips that dose. This flexibility can suit people with irregular mealtimes, provided they understand the rule.

Hypoglycaemia and how meglitinides differ from sulfonylureas

Hypoglycaemia is the most important adverse effect, and risk rises when meals are delayed, when alcohol is taken or when the drug is combined with metformin or other glucose-lowering agents. Teach the signs of low glucose, such as shakiness, sweating, confusion and palpitations, and how to treat a low with fast-acting carbohydrate.

Compared with sulfonylureas, meglitinides act for a shorter time, so lows tend to be less prolonged, but they must be dosed with meals several times a day. Both classes can cause weight gain. Repaglinide is described as a safer choice than some secretagogues in chronic kidney disease, but liver impairment needs caution.

Interactions and monitoring that matter

Repaglinide is metabolised by CYP2C8 and CYP3A4. Gemfibrozil is contraindicated with repaglinide, and clopidogrel is best avoided, because both can raise its levels and cause severe hypoglycaemia; other inhibitors such as clarithromycin and certain azole antifungals need caution. Ask about new prescriptions, including those started by other prescribers.

Monitoring includes capillary glucose before and after meals, HbA1c trends and any hypoglycaemia episodes, with particular attention when meals change in hospital. A patient who is nil by mouth for a procedure should not take a meal-timed dose; confirm the plan with the prescriber rather than giving it on the usual schedule.

Hospital practice: hold, report and coordinate meals

In hospital, give a meglitinide only when the meal tray has arrived or eating is about to begin, and hold it if the patient is nil by mouth, vomiting or eating very little. Check the capillary glucose beforehand and follow the hypoglycaemia protocol for low readings, then notify the prescriber.

Report repeated low readings, poor appetite, new liver impairment or new prescriptions for interacting drugs. At handover, state which meals have been eaten and which doses given or held, so the next nurse does not give a dose to a patient who is not eating. Coordination with dietary staff prevents mismatched timing.

An original scenario and teaching check

In a hypothetical case, a patient taking repaglinide before meals tells the nurse she will skip lunch today because of a long meeting. Options are to take the dose anyway to keep levels steady, double the dinner dose, or skip the lunchtime dose and take the next dose before dinner. Skipping the lunchtime dose is correct, because the drug is matched to food intake. Doubling the dinner dose is the dangerous distractor, because it creates a large insulin surge that the evening meal may not match. Taking the dose anyway risks hypoglycaemia in the middle of her meeting.

Ask for teach-back: when to take the dose, what to do if a meal is missed, how to recognise and treat a low, and why to check with the team before starting new medicines. A patient who says she will take all three doses with breakfast to save time needs further teaching.

Sources and further reading

StatPearls: Repaglinide. Mechanism, pre-meal timing, skipping with missed meals, hypoglycaemia, CYP2C8 interactions with gemfibrozil and clopidogrel, renal and hepatic considerations.

StatPearls: Oral Antidiabetic Medications. Meglitinide versus sulfonylurea duration, hypoglycaemia severity, weight gain and meal-dependent dosing.

DailyMed: Repaglinide tablets prescribing information. Gemfibrozil contraindication, advice to avoid clopidogrel, and taking the dose within 30 minutes before meals.